Efficacy of Aflibercept (Eylea®) on Choroidal Neovascularization (Type 3)
Status:
Completed
Trial end date:
2018-11-01
Target enrollment:
Participant gender:
Summary
This is a one-year pilot, interventional, prospective, single arm, non-randomized,
multicentric (3 centers) controlled study that aims to evaluate the response of type 3
choroidal neovascularization to treatment by Aflibercept following a classic protocol.